Rockefeller University

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. MacroGenics Gets $40m Up Front For St

The approval of the first genetic medicines for sickle cell disease (SCD) on the eve of the American Society of Hematology (ASH) annual meeting set off a celebratory feel for the conference, held 9-12

Germany’s BI Licenses Tumor-Specific Antibodies From Singapore Lab Boehringer Ingelheim GmbH and Singapore’s Agency for Science, Technology and Research (A*STAR) unveiled a global licensing agreem

Tumor-infiltrating lymphocytes have long been regarded as a promising modality for treating solid tumor cancers with cell therapy, but an ongoing challenge in tapping that potential has been manufactu